Literature DB >> 3919978

Interferon-gamma production by peripheral blood leucocytes from patients with multiple sclerosis and other neurological diseases.

G Vervliet, H Carton, A Billiau.   

Abstract

Peripheral blood leucocyte (PBL) cultures of patients with meningoencephalitis, myasthenia gravis, Alzheimer's dementia, Huntington's chorea as well as patients who were recovering from cerebrovascular accidents or from craniotomy for brain tumours, all had defective interferon-gamma (IFN-gamma) responses to stimulation with concanavalin A (Con A) and phytohaemagglutinin (PHA), similar to those already described for PBL cultures of patients with multiple sclerosis. Specifically, cultures from a significant percentage of the patients failed to produce IFN after stimulation with either of the two mitogens. The yields from those cultures that did respond were not significantly lower than those from cultures of healthy blood donors. With increased doses of Con A, the cerebrovascular accident, meningo-encephalitis and MS groups kept their low response frequencies, while the other groups, i.e., myasthenia gravis, Alzheimer's dementia, Huntington's chorea and post-craniotomy, developed an increased response frequency. A good concordance was found between responsiveness to Con A and PHA. With pokeweed mitogen (PWM) as an inducer, no reduction in response frequencies or IFN yields were seen in any of the patient groups. Also, in general, yields were higher with PWM than with Con A.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3919978      PMCID: PMC1577129     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  18 in total

1.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

Authors:  G A SCHUMACHER; G BEEBE; R F KIBLER; L T KURLAND; J F KURTZKE; F MCDOWELL; B NAGLER; W A SIBLEY; W W TOURTELLOTTE; T L WILLMON
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

2.  Genetic control of suppressor lymphocyte function in myasthenia gravis: relationship of impaired suppressor function to HLA-B8/DRW3 and cold reactive lymphocytotoxic antibodies.

Authors:  P J Zilko; R L Dawkins; K Holmes; C Witt
Journal:  Clin Immunol Immunopathol       Date:  1979-10

3.  Neurologic impairment in multiple sclerosis and the disability status scale.

Authors:  J F Kurtzke
Journal:  Acta Neurol Scand       Date:  1970       Impact factor: 3.209

4.  Interferons and the immune system.

Authors:  B R Bloom
Journal:  Nature       Date:  1980-04-17       Impact factor: 49.962

5.  Interferon responses of leukocytes in multiple sclerosis.

Authors:  P A Neighbour; A E Miller; B R Bloom
Journal:  Neurology       Date:  1981-05       Impact factor: 9.910

6.  Network of immune-neuroendocrine interactions.

Authors:  H Besedovsky; E Sorkin
Journal:  Clin Exp Immunol       Date:  1977-01       Impact factor: 4.330

7.  Identification of two serum components regulating the expression of T-lymphocyte function in childhood myasthenia gravis.

Authors:  A Shore; S Limatibul; H M Dosch; E W Gelfand
Journal:  N Engl J Med       Date:  1979-09-20       Impact factor: 91.245

8.  Immunological studies in senile dementia of the Alzheimer type: evidence for enhanced suppressor cell activity.

Authors:  A E Miller; P A Neighbour; R Katzman; M Aronson; R Lipkowitz
Journal:  Ann Neurol       Date:  1981-12       Impact factor: 10.422

9.  Loss of suppressor T cells in active multiple sclerosis. Analysis with monoclonal antibodies.

Authors:  E L Reinherz; H L Weiner; S L Hauser; J A Cohen; J A Distaso; S F Schlossman
Journal:  N Engl J Med       Date:  1980-07-17       Impact factor: 91.245

10.  Suppressive serum, suppressor lymphocytes, and death from burns.

Authors:  J H Wolfe; I Saporoschetz; A E Young; N E O'Connor; J A Mannick
Journal:  Ann Surg       Date:  1981-04       Impact factor: 12.969

View more
  3 in total

1.  CD4 subsets (CD45RA/RO) exhibit differences in proliferative responses, IL-2 and gamma-interferon production during intravenous methylprednisolone treatment of multiple sclerosis.

Authors:  A D Crockard; M T Treacy; A G Droogan; S A Hawkins
Journal:  J Neurol       Date:  1996-06       Impact factor: 4.849

2.  Interferon gamma production by human intestinal mucosal mononuclear cells. Decreased levels in inflammatory bowel disease.

Authors:  B Y Lieberman; C Fiocchi; K R Youngman; W K Sapatnekar; M R Proffitt
Journal:  Dig Dis Sci       Date:  1988-10       Impact factor: 3.199

3.  Natural cytotoxic activity in multiple sclerosis patients: defects in IL-2/interferon gamma-regulatory circuit.

Authors:  E Braakman; A van Tunen; A Meager; C J Lucas
Journal:  Clin Exp Immunol       Date:  1986-11       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.